ARVN250117P35000
- 10.20
- 0.000.00%
Arvinas Newsroom
Oppenheimer Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $40
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and VolitionRX (VNRX)
BTIG Initiates Arvinas(ARVN.US) With Buy Rating, Announces Target Price $69
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $57
Arvinas Holding Company: Strategic Pipeline Advancements and Promising Clinical Developments Justify Buy Rating
BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Raises Target Price to $57
Analysts' Opinions Are Mixed on These Healthcare Stocks: Outset Medical (OM), Arvinas Holding Company (ARVN) and Innovent Biologics (OtherIVBXF)
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Buy Rating for Arvinas Holding Company Driven by Vepdeg's Promising Potential and Market Opportunity
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Evercore Initiates Arvinas(ARVN.US) With Buy Rating, Announces Target Price $110
Arvinas Holding Company (ARVN) Receives a Buy From Evercore ISI
Arvinas Analyst Ratings
H.C. Wainwright Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $87
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Promising Potential and Strong Efficacy of Arvinas Holding's Vepdeg+Abema Combination Drive Buy Rating
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $67
BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $88